List of Excipients in Branded Drug EFAVIRENZ

Generic Drugs Containing EFAVIRENZ

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	efavirenz	0378-2233	CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc	efavirenz	0378-2233	CROSCARMELLOSE SODIUM
Mylan Pharmaceuticals Inc	efavirenz	0378-2233	FERRIC OXIDE RED
Mylan Pharmaceuticals Inc	efavirenz	0378-2233	FERRIC OXIDE YELLOW
Mylan Pharmaceuticals Inc	efavirenz	0378-2233	HYDROXYPROPYL CELLULOSE
Mylan Pharmaceuticals Inc	efavirenz	0378-2233	HYPROMELLOSE

What are the Most Frequently-Used Excipients in EFAVIRENZ?

# Of NDCs	Excipient
2	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
12	CELLULOSE, MICROCRYSTALLINE
13	CROSCARMELLOSE SODIUM
1	CROSPOVIDONE
6	FERRIC OXIDE RED
16	FERRIC OXIDE YELLOW

Efavirenz Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Efavirenz is an established non-nucleoside reverse transcriptase inhibitor with extensive generic competition and limited originator exclusivity. The main formulation challenge is its very low aqueous solubility, which makes excipient selection central to dissolution, bioavailability, dose uniformity, pediatric acceptability, and manufacturing cost. The strongest commercial opportunities are differentiated pediatric products, low-cost fixed-dose combinations, taste-masked dispersible tablets, and formulations that improve dissolution without adding complex cold-chain or device requirements.

What formulation problems must efavirenz excipients solve?

Efavirenz is practically insoluble in water and has dose-dependent absorption characteristics. It is administered orally, generally at a 600 mg adult dose, and is associated with central nervous system adverse effects, gastrointestinal symptoms, and an unpleasant taste that complicates pediatric use. The reference product, Sustiva, was marketed as capsules and tablets, while generic products have used tablets, capsules, and fixed-dose combinations.[1,2]

Efavirenz excipients must address five technical requirements:

1. Improve wetting and dissolution of the hydrophobic drug.
2. Maintain content uniformity at lower pediatric strengths.
3. Support high-dose tablet manufacture without excessive tablet size.
4. Mask bitterness and reduce powder segregation.
5. Preserve stability under tropical conditions common in HIV treatment programs.

Efavirenz is commonly treated as a poorly soluble, highly permeable compound. Its formulation performance therefore depends heavily on particle size, solid-state form, wetting, supersaturation control, and dissolution testing.

Core physicochemical profile

Attribute	Formulation relevance
Active ingredient	Efavirenz
Therapeutic class	Non-nucleoside reverse transcriptase inhibitor
Adult dose	Commonly 600 mg once daily
Solubility	Very low in water
Permeability	High relative to solubility
Main dosage forms	Tablets, capsules, fixed-dose combinations
Key formulation risk	Inadequate dissolution and variable exposure
Main patient-use issue	Bitter taste and neuropsychiatric tolerability
Storage target	Stable under controlled room-temperature conditions
Commercial setting	Generic, public-health and combination-product markets

The label for Sustiva states that efavirenz should be taken on an empty stomach because food, particularly high-fat food, can increase exposure.[1] This creates an important formulation constraint. A formulation designed to increase dissolution must avoid producing excessive or unpredictable food-effect amplification.

Which excipients are most suitable for efavirenz?

The most useful excipient strategy combines a surface-area or solid-state intervention with a robust tablet platform. A simple direct-compression formula can be commercially attractive, but it may not provide sufficient dissolution for all particle-size distributions or manufacturing sites.

Solubilizers and wetting agents

Surfactants can improve wetting and dissolution of efavirenz. Candidate materials include:

• Sodium lauryl sulfate
• Poloxamers
• Polyoxyethylene-based surfactants
• Docusate sodium in selected systems
• Low concentrations of polysorbates for liquid or dispersion products

Sodium lauryl sulfate is effective but can create risks involving tablet lubrication, taste, gastrointestinal tolerability, and dissolution overshoot. It should be screened across a narrow concentration range rather than treated as a default high-load excipient.

Poloxamer 188 and poloxamer 407 can improve wetting and support amorphous dispersions or nanosized systems. Their use requires attention to hygroscopicity, compression behavior, and potential recrystallization of efavirenz during storage.

Hydrophilic polymers for amorphous solid dispersions

Hydrophilic polymers can maintain efavirenz in a higher-energy amorphous state and improve apparent solubility. Relevant candidates include:

• Copovidone
• Povidone K30 or K90
• Hypromellose
• Hypromellose acetate succinate
• Polyethylene glycol
• Soluplus-type graft copolymers

Copovidone and hypromellose are commercially practical for hot-melt extrusion, spray drying, or solvent-based processing. Hypromellose acetate succinate can provide stronger precipitation inhibition, but its use may increase process complexity and cost.

The principal risk is physical instability. An amorphous formulation can lose its dissolution advantage if efavirenz recrystallizes during accelerated or long-term storage. Excipient selection must therefore be linked to moisture control, residual-solvent limits, packaging, and solid-state characterization.

Disintegrants and compression aids

For immediate-release tablets, suitable disintegrants include:

• Croscarmellose sodium
• Crospovidone
• Sodium starch glycolate

Crospovidone can provide rapid liquid uptake and is useful in direct-compression systems. Croscarmellose sodium may deliver strong swelling and wicking performance but can be sensitive to compression force and formulation density.

Microcrystalline cellulose remains a practical diluent for high-dose tablets. Dibasic calcium phosphate can improve flow and tablet hardness but may reduce performance if the formulation depends on rapid liquid penetration. Lactose is widely used, although compatibility, moisture, and Maillard-reaction considerations must be evaluated when combined with amine-containing excipients or other formulation components.

Lubricants and glidants

Magnesium stearate is widely used, but over-lubrication can slow wetting and dissolution. For a poorly soluble drug, lubricant concentration and blending time require tighter process control than in a highly soluble product.

Colloidal silicon dioxide can improve flow and reduce segregation, particularly when micronized efavirenz is blended with low-dose pediatric excipients. Its impact on powder rheology and tablet tensile strength should be assessed at commercial scale.

What formulation technologies can improve efavirenz dissolution?

The strongest technologies are those that improve dissolution without materially increasing manufacturing cost or regulatory burden.

Micronization

Micronization is the lowest-complexity approach. Reduced particle size increases surface area and can improve dissolution, but it does not eliminate the underlying solubility limitation. Micronized efavirenz also creates powder-flow, electrostatic, containment, and segregation risks.

A micronized product is most commercially attractive when paired with:

• A wetting agent
• A high-performing disintegrant
• Controlled blending
• Tight particle-size specifications
• Protective packaging

Micronization alone may be insufficient for pediatric doses or low-strength combination tablets.

Solid dispersions

Solid dispersions can provide a larger dissolution improvement than micronization. Spray drying with copovidone, povidone, hypromellose, or a surfactant-polymer system is a plausible platform for efavirenz.

Commercial advantages include stronger dissolution performance and potential reduction in dose-related variability. Disadvantages include solvent handling, residual-solvent control, higher capital requirements, and physical-stability risk.

Hot-melt extrusion avoids organic solvents but requires thermal stability and careful torque and temperature control. The process may be less attractive for a low-margin antiretroviral unless the product has a clear pediatric or differentiated-market benefit.

Nanocrystals and nanosuspensions

Efavirenz nanocrystals can increase dissolution rate and may support lower-dose pediatric products or liquid dispersions. The technology can be delivered through wet milling or high-pressure homogenization.

The commercial barriers are meaningful:

• Particle-size control during scale-up
• Stabilizer selection
• Ostwald ripening
• Sedimentation or aggregation in liquid products
• Microbial control for aqueous suspensions
• More demanding analytical release methods

Nanocrystals are most relevant where a conventional tablet cannot meet dissolution or where an oral pediatric product has significant procurement value.

Lipid-based systems

Self-emulsifying or lipid-based systems may improve solubilization, but they are less natural fits for a high-dose, low-cost efavirenz tablet. They may be relevant to softgels, oral liquids, or specialty products, but food-effect behavior and excipient tolerability must be closely controlled.

What excipient strategy is best for adult efavirenz tablets?

For a standard adult generic, the preferred strategy is usually a low-cost immediate-release tablet with micronized efavirenz, a hydrophilic diluent, a rapid disintegrant, a controlled amount of surfactant, and conservative lubrication.

A practical development sequence is:

1. Establish the dissolution profile of the target reference product.
2. Screen micronized and nonmicronized efavirenz.
3. Compare sodium lauryl sulfate, poloxamer, and polymeric wetting systems.
4. Optimize disintegrant type and level.
5. Evaluate lubricant concentration and blending time.
6. Confirm food-effect implications through comparative dissolution and bioequivalence planning.
7. Test stability under high temperature and humidity.
8. Lock particle-size and solid-state specifications.

The commercial objective is not maximum solubilization. It is reproducible release that meets bioequivalence requirements at the lowest viable cost.

What excipients are needed for pediatric efavirenz products?

Pediatric formulation is the clearest technical opportunity. Children may require oral granules, sprinkles, dispersible tablets, powders for suspension, or low-strength tablets. The primary challenge is taste. Efavirenz is strongly bitter, and conventional sweetening alone is unlikely to produce acceptable palatability.

Pediatric excipient priorities

Product type	Preferred excipient functions
Dispersible tablet	Rapid disintegration, taste masking, wetting
Oral granules	Coating, flow control, bitterness reduction
Powder for suspension	Suspending agent, wetting agent, preservative if aqueous
Sprinkle formulation	Multiparticulate coating, low dust, dose uniformity
Low-strength tablet	Content uniformity, direct compression, segregation control

Potential taste-masking systems include polymer coating, lipid coating, ion-pairing approaches, complexation, and multiparticulate encapsulation. Coating materials may include ethylcellulose, hypromellose, methacrylate copolymers, or lipid excipients. The coating must release efavirenz rapidly after administration while limiting contact with taste receptors.

The pediatric opportunity is strengthened by the regulatory and public-health emphasis on age-appropriate antiretroviral dosage forms. The U.S. Food and Drug Administration approved Sustiva capsules and tablets for HIV-1 treatment and included pediatric dosing information, but the commercial market has moved toward generic and combination products.[1] Global HIV programs continue to prioritize formulations that reduce swallowing burden and improve adherence.[3]

What fixed-dose combination opportunities exist for efavirenz?

Efavirenz has been used in combination products with tenofovir disoproxil fumarate and emtricitabine, including Atripla and generic equivalents. Fixed-dose combinations reduce pill burden but create a more difficult excipient and manufacturing problem because the formulation must accommodate multiple active ingredients with different solubility, compressibility, particle-size, and stability profiles.

Combination-product development must manage:

• Differential dissolution of efavirenz and nucleoside reverse transcriptase inhibitors
• Drug-drug and excipient compatibility
• Tablet size at high total drug load
• Layering or granulation strategy
• Content uniformity across multiple actives
• Distinct degradation pathways
• Bioequivalence requirements for the complete product

The most practical commercial route is a high-load immediate-release tablet supported by particle engineering and dry granulation or optimized direct compression. A multilayer tablet can separate incompatible ingredients but may increase manufacturing cost.

What is the FDA regulatory and Orange Book status of efavirenz?

Efavirenz is an FDA-approved active ingredient with generic availability. Sustiva was approved in 1998, and the FDA label identifies Bristol-Myers Squibb as the original sponsor.[1] Atripla, containing efavirenz, emtricitabine, and tenofovir disoproxil fumarate, was approved in 2006 and was developed through collaboration between Bristol-Myers Squibb and Gilead Sciences.[4]

Originator patent protection for the core efavirenz product has expired in the United States. The relevant commercial question is therefore not whether efavirenz remains protected by broad composition-of-matter exclusivity. It is whether a specific formulation, combination, method of use, manufacturing process, or jurisdiction-specific patent creates a residual barrier.

Orange Book-listed patents, if any remain relevant for a particular reference product or dosage form, must be reviewed against the current FDA publication and the specific abbreviated new drug application. Generic applicants may face Paragraph IV issues when an unexpired listed patent covers the reference product. For an established active ingredient such as efavirenz, residual risk is more likely to arise from formulation or combination claims than from the active pharmaceutical ingredient itself.[5]

When does efavirenz lose exclusivity, and what generic entry risks exist?

The core efavirenz market is already generic. Adult generic entry risk is high, particularly for conventional tablets and capsules. The residual opportunity for patent protection is concentrated in differentiated delivery systems.

Potentially defensible areas include:

• Taste-masked pediatric multiparticulates
• Specific amorphous solid dispersions
• Nanocrystal compositions
• Controlled-release or food-effect-modifying formulations
• Stable liquid suspensions
• Combination tablets with defined manufacturing controls
• Novel packaging and moisture-protection systems, where claim scope is meaningful

These rights may face validity and enforceability pressure if prior art discloses similar polymers, particle-size reductions, surfactant systems, or standard antiretroviral combinations. A formulation patent is stronger when it links a narrowly defined composition to unexpected dissolution, bioavailability, stability, or palatability results.

Which companies and products compete with efavirenz?

Competition comes from two directions: generic efavirenz products and newer antiretroviral regimens.

Competitive segment	Commercial effect
Generic efavirenz tablets and capsules	Price pressure and limited differentiation
Efavirenz-based fixed-dose combinations	Lower pill burden and public-procurement relevance
Dolutegravir-based regimens	Clinical and guideline pressure on efavirenz
Pediatric dispersible antiretrovirals	Potential niche for differentiated efavirenz products
Long-acting antiretrovirals	Structural challenge to daily oral therapy

WHO treatment guidance has shifted toward dolutegravir-based regimens for many populations because of efficacy, resistance profile, and tolerability considerations.[3] Efavirenz remains relevant where cost, existing procurement systems, resistance considerations, pregnancy-related treatment policies, or local formularies support its use.

How strong is the efavirenz formulation patent estate?

The broad patent estate is weak from a commercial exclusivity perspective because efavirenz has been marketed for decades and conventional dosage forms are heavily disclosed. New formulation patents can still be valuable, but their strength depends on claim specificity and comparative data.

A stronger patent position would include:

• Narrow particle-size or solid-state definitions
• Defined polymer-to-drug ratios
• Demonstrated resistance to recrystallization
• Clinically meaningful dissolution or exposure improvement
• Taste-masking performance supported by human or validated sensory data
• Manufacturing claims that solve scale-up problems
• Protection across tablets, granules, and pediatric dosage forms

A weak position would rely on routine substitution of common excipients, broad lists of polymers, or predictable combinations of micronization and disintegrants.

What licensing and partnering opportunities exist?

The most credible licensing targets are technology platforms rather than the efavirenz molecule. Potential transaction structures include:

• Licensing a pediatric taste-masking platform to a generic HIV manufacturer
• Supplying a proprietary efavirenz solid dispersion intermediate
• Partnering with a public-health manufacturer on dispersible tablets
• Licensing a stable nanosuspension process for low-resource markets
• Developing a fixed-dose combination under a regional commercialization agreement

The Atripla collaboration between Bristol-Myers Squibb and Gilead demonstrates the commercial value of combining antiretroviral assets, although the originator economics and market conditions differ materially from current generic opportunities.[4] Current partnerships are more likely to center on manufacturing, technology transfer, procurement access, and regulatory dossiers than on exclusive molecule rights.

What manufacturing and geographic barriers affect efavirenz products?

Manufacturing barriers are moderate for conventional tablets and high for advanced dispersions or nanosuspensions. The most important geographic variables are climate, procurement channel, regulatory pathway, and pediatric demand.

Geographic considerations

• United States: mature generic market, FDA ANDA pathway, limited room for undifferentiated adult tablets.
• European Union: decentralized or centralized regulatory strategies may support combination or pediatric products, but competition is established.
• Sub-Saharan Africa: large public-health demand, price sensitivity, heat and humidity stress, and value in dispersible or simplified products.
• South and Southeast Asia: significant generic manufacturing capacity and potential contract-development opportunities.
• Latin America: country-specific registration and procurement dynamics, with demand for cost-efficient fixed-dose combinations.

For tropical markets, packaging can be as important as excipient selection. High-barrier blisters, desiccants, and moisture-controlled packaging may protect an amorphous or surfactant-containing formulation more effectively than additional stabilizing excipients.

What is the commercial outlook for efavirenz excipient innovation?

The adult efavirenz market has limited opportunity for premium pricing. A conventional tablet based on standard excipients is unlikely to command durable differentiation. The stronger opportunities are:

1. Pediatric taste-masked products.
2. Low-dose dispersible tablets.
3. Stable oral powders or granules.
4. Affordable fixed-dose combinations.
5. Manufacturing platforms that reduce solvent use or improve scale-up.
6. Products optimized for hot and humid supply chains.

Revenue exposure for originator companies is low relative to newer antiretroviral products. Generic manufacturers can still generate volume through public procurement, but margins depend on manufacturing efficiency, regulatory approvals, and tender access. Advanced excipient systems make commercial sense only when they solve a defined clinical or procurement problem.

Key Takeaways

• Efavirenz is a poorly water-soluble, highly permeable antiretroviral whose performance depends on dissolution and solid-state control.
• Micronization, surfactants, hydrophilic polymers, amorphous dispersions, and nanocrystals are the main formulation tools.
• Adult immediate-release tablets are a mature, price-competitive generic market.
• Pediatric taste masking and dispersible delivery offer the clearest formulation opportunity.
• Efavirenz-based fixed-dose combinations remain commercially relevant but face competition from dolutegravir-based regimens.
• Core molecule exclusivity has expired; residual patent value is concentrated in narrow formulations, manufacturing processes, and pediatric delivery systems.
• Moisture protection, content uniformity, and tropical stability are important for global-market products.
• The best commercial strategy is a low-cost formulation with a measurable advantage in palatability, dissolution, stability, or procurement utility.

FAQs

Can efavirenz be formulated as an oral suspension?

Yes. An oral suspension is technically feasible using micronized efavirenz or a nanosuspension approach, combined with wetting, suspending, viscosity-control, flavoring, and preservation systems. The main risks are sedimentation, redispersion, dose uniformity, bitterness, and physical stability.

Which polymer is most promising for an efavirenz amorphous solid dispersion?

Copovidone, povidone, hypromellose, and hypromellose acetate succinate are credible candidates. The best polymer depends on drug loading, process temperature, moisture exposure, dissolution targets, and resistance to recrystallization.

Does efavirenz require a lipid formulation?

No. Lipid systems can improve solubilization, but conventional tablets, solid dispersions, micronized products, and nanocrystals are generally more practical for high-volume antiretroviral markets.

Can a new efavirenz excipient combination support patent protection?

Potentially, but routine combinations of known excipients are vulnerable to obviousness challenges. Stronger protection requires a defined composition and evidence of unexpected dissolution, stability, bioavailability, palatability, or manufacturing performance.

Is efavirenz still commercially attractive for generic manufacturers?

Yes, primarily through public-health procurement, fixed-dose combinations, pediatric products, and efficient manufacturing. The opportunity is weaker for undifferentiated adult tablets because of established generic competition and competition from newer HIV regimens.

References

1. U.S. Food and Drug Administration. (2016). Sustiva (efavirenz) prescribing information. Bristol-Myers Squibb Company.

2. National Library of Medicine. (2024). Efavirenz: Drug label information. DailyMed.

3. World Health Organization. (2021). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: Recommendations for a public health approach. World Health Organization.

4. U.S. Food and Drug Administration. (2006). Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate) prescribing information. Bristol-Myers Squibb and Gilead Sciences.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.